Novo Nordisk A/S $NVO Shares Purchased by Prospera Financial Services Inc

Prospera Financial Services Inc boosted its holdings in Novo Nordisk A/S (NYSE:NVO) by 5.0% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 441,858 shares of the company’s stock after acquiring an additional 21,063 shares during the period. Prospera Financial Services Inc’s holdings in Novo Nordisk A/S were worth $22,483,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in the business. Quotient Wealth Partners LLC lifted its holdings in Novo Nordisk A/S by 2.0% in the fourth quarter. Quotient Wealth Partners LLC now owns 9,091 shares of the company’s stock valued at $463,000 after acquiring an additional 177 shares during the last quarter. Certuity LLC raised its position in Novo Nordisk A/S by 3.6% in the fourth quarter. Certuity LLC now owns 5,052 shares of the company’s stock valued at $257,000 after purchasing an additional 177 shares during the period. Oakworth Capital Inc. raised its position in Novo Nordisk A/S by 41.6% in the fourth quarter. Oakworth Capital Inc. now owns 619 shares of the company’s stock valued at $31,000 after purchasing an additional 182 shares during the period. True North Advisors LLC raised its position in Novo Nordisk A/S by 3.9% in the fourth quarter. True North Advisors LLC now owns 5,305 shares of the company’s stock valued at $270,000 after purchasing an additional 199 shares during the period. Finally, Asio Capital LLC raised its position in Novo Nordisk A/S by 3.9% in the fourth quarter. Asio Capital LLC now owns 5,386 shares of the company’s stock valued at $274,000 after purchasing an additional 200 shares during the period. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: European regulators recommended approval of Novo Nordisk’s Wegovy 7.2 mg pen, with trial data showing up to 20.7% mean weight loss, strengthening the company’s obesity-drug pipeline and supporting future EU sales. Article Title
• Positive Sentiment: The CHMP also recommended approval for Novo Nordisk’s Wegovy pill, potentially making it the first oral GLP-1 obesity drug in the EU and broadening the company’s treatment options. Article Title
• Positive Sentiment: Reuters reported Novo is using AI to speed drug development and expand its role in India, which could help it bring new products to market faster and regain momentum in obesity. Article Title
• Neutral Sentiment: Industry chatter about Lilly’s obesity-drug breakthrough and reports that both Lilly and Novo drugs may have cancer-prevention benefits highlight strong demand in the class, but also underscore intensifying competition and a larger long-term market. Article Title
• Negative Sentiment: Eli Lilly’s retatrutide posted about 28% weight loss in late-stage testing, setting a new benchmark that increases pressure on Novo Nordisk to keep innovating in obesity and GLP-1 therapies. Article Title

Novo Nordisk A/S Stock Up 1.2%

Novo Nordisk A/S stock opened at $44.91 on Friday. Novo Nordisk A/S has a twelve month low of $35.12 and a twelve month high of $81.44. The stock’s fifty day simple moving average is $40.29 and its 200-day simple moving average is $46.46. The company has a current ratio of 0.79, a quick ratio of 0.56 and a debt-to-equity ratio of 0.59. The firm has a market capitalization of $200.52 billion, a P/E ratio of 10.54, a P/E/G ratio of 4.01 and a beta of 0.77.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings data on Tuesday, March 31st. The company reported $1.03 earnings per share for the quarter. Novo Nordisk A/S had a return on equity of 63.31% and a net margin of 37.23%.The business had revenue of $10.85 billion for the quarter. As a group, equities analysts expect that Novo Nordisk A/S will post 3.46 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have issued reports on NVO. Jefferies Financial Group raised Novo Nordisk A/S from an “underperform” rating to a “hold” rating in a research report on Thursday, February 12th. Zacks Research raised Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a research report on Tuesday, March 10th. Sanford C. Bernstein began coverage on Novo Nordisk A/S in a research report on Wednesday, March 18th. They issued an “outperform” rating and a $175.00 target price on the stock. Nordea Equity Research lowered Novo Nordisk A/S to a “hold” rating in a research report on Tuesday, February 24th. Finally, Wall Street Zen raised Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research report on Saturday, May 16th. Four equities research analysts have rated the stock with a Buy rating, eighteen have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $65.56.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.